Lartruvo
NDC Package 0002-8926-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Lartruvo is a medication used to treat a certain type of cancer (soft tissue sarcoma). Marketed by Eli Lilly And Company, this product is identified by NDC 0002-8926 and is authorized under FDA application BLA761038.

Identification & Billing

NDC Package Code
0002-8926-01
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 50 mL in 1 VIAL, SINGLE-USE
Product Code
0002-8926
11-Digit Billing Format
00002892601
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.

Clinical Specifications

Proprietary Name
Lartruvo
Dosage Form
-
Usage Information
This medication is used to treat a certain type of cancer (soft tissue sarcoma). Talk to your doctor about the benefits and risks of treatment with olaratumab. In Europe, this medication is being withdrawn from the market due to lack of effectiveness in a clinical study. This medication belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Eli Lilly And Company
FDA Application #
BLA761038
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-19-2016
End Marketing Date
11-28-2020
Listing Expiration
11-28-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0002-8926-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 50 ml in 1 vial, single-use of Lartruvo, labeled by Eli Lilly And Company. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Eli Lilly And Company on October 19, 2016. The current certification is valid through November 28, 2020.

What are the primary indications for this medication?

This medication is used to treat a certain type of cancer (soft tissue sarcoma). Talk to your doctor about the benefits and risks of treatment with olaratumab. In Europe, this medication is being withdrawn from the market due to lack of effectiveness in a clinical study. This medication belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

How is this Eli Lilly And Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002892601. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0002-8926-01
11-Digit CMS (5-4-2)
00002-8926-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.